Newsroom

Sight Sciences to Report Second Quarter 2023 Financial Results on August 3, 2023

PDF Version MENLO PARK, Calif., July 20, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative technology intended to transform...

read more +
Sight Sciences Announces Addition of New Director Catherine Mazzacco

PDF Version MENLO PARK, Calif., June 09, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on creating innovative solutions...

read more +
Sight Sciences Reports First Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023

PDF Version MENLO PARK, Calif., May 04, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on creating innovative solutions...

read more +
Sight Sciences to Report First Quarter 2023 Financial Results on May 4, 2023

PDF Version MENLO PARK, Calif., April 20, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and...

read more +
Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer

PDF Version Ali Bauerlein Ali Bauerlein has been appointed Sight Sciences’ Chief Financial Officer and Treasurer, effective April 3, 2023 MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) — Sight...

read more +
Sight Sciences Reports Fourth Quarter and Full Year 2022 Financial Results

PDF Version MENLO PARK, Calif., March 13, 2023 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on creating innovative solutions...

read more +
Sight Sciences Reports Third Quarter 2022 Financial Results

PDF Version MENLO PARK, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and...

read more +
Sight Sciences Announces Publication of Clinical Data Demonstrating Standalone Effectiveness of the OMNI® Surgical System in Pseudophakic Glaucoma Patients with Uncontrolled Pressure Following a Previous Combination Cataract Stent Procedure

Multicenter Clinical Data from Five US sites Published in International Ophthalmology Worldwide, more than one million trabecular microbypass stents have been implanted in combination with cataract surgery. Despite glaucoma medications and prior microbypass stenting, target IOP may no longer be achieved over time. During 3 to 42 months follow-up, the majority of these standalone study patients treated with OMNI regained IOP control and avoided traditional surgery.

read more +